ACCESS Newswire
20 Sep 2023, 15:13 GMT+10
WASHINGTON, D.C. / ACCESSWIRE / September 20, 2023 / MMJ International Holdings announced today, that it has submitted to the U.S. Food and Drug Administration (FDA) MMJ's cannabis formulation requested responses for the agency's review. The FDA had notified MMJ International Holdings of a CMC (chemistry, manufacturing, control) issue which the company completed the required complex scientific research needed to begin its clinical trials in Multiple Sclerosis and Huntington's Disease.
Dr. Elio Mariani, MMJ's chief scientific stated, 'MMJ believes that the responses submitted to the FDA today fully addresses the CMC questions pertaining to its all-natural plant, soft gel capsule API of THC and CBD, for use in human clinical trials.'
Duane Boise, President stated, 'Once approved, MMJ International Holdings, MMJ BioPharma Cultivation, and MMJ Biopharma Labs will be one of a very few federally legal DEA, FDA approved companies, vertically integrated, with the infrastructure to support pharmaceutical development of botanical drugs for clinical trials.'
MMJ BioPharma Labs has been issued a DEA Analytical Lab Registration for schedule 1 drugs with the primary focus on cannabis research and development. With this DEA approval, MMJ Biopharma Labs becomes one of the few federally legal labs dedicated to cannabis extraction, research, and development.
This DEA approval allows MMJ BioPharma Labs the ability to manufacture, transport, import, and export cannabis domestically and internationally to DEA registrants and companies registered in their respective international jurisdictions.
In spite of all these accomplishments and President Biden's Marijuana Research Act approval the DEA continues to delay MMJ BioPharma Cultivations API Bulk Manufacturing registration approval which is the subject of litigation.
Tim Moynahan, chairman stated 'MMJ has accomplished many major milestones which positions it as a leader in the cannabis pharmaceutical development arena. This being the most significant because safe, reproducible marijuana medicine is needed to set the standard for reproducible results. MMJ's clinical trials will prove efficacy and this is what the team has accomplished.'
MMJ recognizes that there is significant public interest in cannabis and cannabis-derived compounds. The MMJ team continues to work diligently with universities and scientist to fill in the knowledge gaps about the science, safety and quality of their products. We are committed to advancing our marijuana cultivation, lab formulations and clinical trials through an approach that is in line with our mission to prioritizes public health, fosters innovation, and promotes consumer confidence.
Duane Boise the companies President recently speaking at the Benzinga Cannabis Forum mentioned that 'as federal legalization of the state to state recreational and medicinal marijuana businesses is not imminent, MMJ's strategy of pharmaceutical drug development and clinical trials will show itself as the new cannabis 3.0.'
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
Get a daily dose of California Telegraph news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to California Telegraph.
More InformationLONDON, U.K.: In a landmark moment for Britain, lawmakers in the House of Commons have voted in favour of legalising assisted dying,...
Western support for Israel's right to strike Iran backs up a pattern of pre-emptive violence that critics say is further eroding international...
OTTAWA, Canada: Canada may boost its counter-tariffs on steel and aluminum imported from the U.S. if a comprehensive trade agreement...
BANGKOK, Thailand: Thailand's government is facing its biggest crisis in nearly a year, as Prime Minister Paetongtarn Shinawatra's...
WASHINGTON, DC - U.S. President Donald Trump how bowed to pro-Israel elements in his administration and Congress, announcing that the...
ZURICH, Switzerland: The Swiss National Bank (SNB) lowered its key interest rate to zero percent on June 19 to respond to falling inflation,...
SANTAREM, Brazil: As Brazil cements its position as the world's top soy exporter, a new wave of deforestation is spreading across the...
ZURICH, Switzerland: A wave of central banks across Europe surprised markets last week by lowering interest rates, responding to easing...
WASHINGTON, D.C.: The U.S. economy is performing reasonably well, but Federal Reserve Chair Jerome Powell faces a difficult decision...
WASHINGTON, D.C.: President Donald Trump has granted TikTok another reprieve, extending the deadline for its Chinese parent company,...
WASHINGTON, D.C.: As the global weight-loss market explodes, drugmakers are now racing to solve a less visible problem: protecting...
HAYWARD, California: In a significant step toward its commercial debut, Amazon-owned Zoox has unveiled its first factory dedicated...